Skip to main content
Premium Trial:

Request an Annual Quote

Accelr8 Reports Preliminary FY2010 Revenues of $2.2M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Accelr8 Technology today reported preliminary revenues of $2.2 million for its fiscal year ended July 31, compared to revenues of $1.3 million for FY 2009.

The Denver-based firm also reported net income of $650,447 for the year, compared to a net loss of $714,197 for the previous year.

Accelr8 also noted that its total shareholders' equity was approximately $4.9 million. Last month, the firm had been notified by the NYSE Amex that it was still not in compliance with listing standards. In order to be listed, the exchange requires that a company have at least $4 million in stockholder equity if it has losses from continuing operations and net losses in three of the four most recent fiscal years.

In early Thursday trade, shares of Accelr8 were up 12 percent at $.90.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.